Introduction {#s1}
============

The annual incidence of hospitalization for acute gastrointestinal bleed (GIB) is 36 per 100,000 population for acute lower GIB and about half of that for upper GIB \[[@R01]\]. Upper GIB has been estimated to account for up to 20,000 deaths annually in the United States \[[@R02]\], while mortality rates ranging between 2% to 10% have been reported for lower GIB \[[@R03]\]. Appropriate risk stratification of patients presenting with acute GIB aids in the triage of patients to determine need for hospital admission and level of in-hospital care, as well as the need for emergent endoscopic intervention.

Several well-validated risk stratification tools have been developed specifically for upper GI bleeds, the most commonly used being the Glasgow-Blatchford score (GBS), Rockall Score, and AIM65 score. Unlike risk scores for upper GIB, there are no risk scores with high generalizability that have been established for acute lower GIB.

Although the use of risk stratification systems are strongly encouraged in current practice guidelines, only 53% of physicians had ever heard of and 30% had ever used an upper GIB risk scores in a nationwide study in the United States \[[@R04]\]. The possible barriers to adherence are not clearly identified. Since separate risk scores are derived for upper and lower GIB, their application in clinical practice dictates accurate clinical determination of the site of GIB, which is not always clear during early evaluation by frontline providers. For instance, approximately 15% of patients with presumed lower GIB are ultimately found to have an upper GIB source for their bleeding \[[@R05]\], underscoring uncertainty in discerning upper vs. lower source of GIB, and therefore limiting the utility of scores specifically developed for upper or lower GIB. There are no risk scores that have been validated for or evaluated in a mixed population of upper and lower GIB.

Existing risk scores already incorporate a variety of laboratory parameters into their formulae: GBS uses Blood Urea Nitrogen (BUN) & Hemoglobin, and AIMS65 uses Albumin & International Normalized Ratio (INR). However, multiple recent studies have demonstrated the significant role Lactic Acid (LA) plays as a predictor of clinical outcomes, demonstrated in upper GIB patients \[[@R06]-[@R11]\] and mixed upper & lower GIB patients \[[@R12], [@R13]\]. In a retrospective study of 331 patients with upper GIB, LA was shown to enhance the performance of two scoring systems (GBS and the post-endoscopic Rockall score) in predicting mortality, although the improvement in prognositic performance might not to be clinically significant \[[@R10]\].

The aim of this study was twofold: 1) To validate existing risk scores (GBS, AIMS65, and RS) to predict in-hospital mortality in unselected patients presenting with acute GIB, suspected of either upper or lower GI bleeds; 2) To evaluate the role of initial venous LA to independently predict mortality and its incremental value to the above clinical risk scores.

Materials and Methods {#s2}
=====================

Study design and patient selection {#s2a}
----------------------------------

We conducted a retrospective analysis of consecutive patients presenting to the emergency department (ED) of a single large academic tertiary care medical center from January 2014 to December 2015 with a charted diagnosis of acute GIB, inclusive of both upper and lower sources. Gastroenterologists and general surgeons are available 24 h daily, 7 days a week for emergent endoscopy or surgery.

The medical records were queried for patients' demographic characteristics, medical history, initial vital signs, laboratory values, and the primary outcome of in-patient mortality status. Chart review of all physician notes written within the first 12 h of presentation was used to determine symptoms of melena, altered mental status and syncope. Endoscopic diagnosis and hemorrhagic stigmata were determined by review of all endoscopic reports. Glasgow-Blatchford Bleeding Score (GBS), AIMS65, pre-endoscopic Rockall (RS-PE) and post-endoscopic Rockall score (RS-C) were calculated for each patients. RS-C was calculated only for the 189 patients who had endoscope.

Statistics {#s2b}
----------

Continuous variables were reported as mean ± standard deviation or median ± interquartile range (IQR) and compared by *t*-test for parametric variables or Mann-Whitney U test for nonparametric variables. Categorical variables were presented as counts (percentages) and compared by using either Chi-square test or Fisher's exact test (for sparse data). A P-value of \< 0.05 was considered statistically significant. Variables found to be statistically significant in univariate analysis were included as candidate covariates in the multivariate logistic regression analysis which was run using forward stepwise selection procedure.

To evaluate the incremental value of LA to clinical risk scores, we generated modified scores (L-GBS, L-RS-PE, and L-RS-C) by adding extra points to the calculated scores if LA level was elevated above the optimal threshold. The optimal cut-off for LA for discriminating in-patient mortality was a value that corresponds to the Youden's-index (maximum value of sensitivity + specificity - 1). The numerical value of the extra point to be added to the risk scores was obtained from the beta coefficient (95% confidence interval (CI)) of a binary logistic regression model in which the variable "lactic acid" was dichotomized into a value above or below the optimal cut-off determined by the Youden's Index. The discriminative ability of the original and modified risk scores for predicting in-hospital mortality was evaluated by calculating the AUC of the receiver operating characteristic (ROC) curves and which were compared using nested logistic regression models.

STATA 14 (StataCorp LLC, College Station, Texas) was used to plot the ROC curves and perform nested logistic regression models to assess the improvement in AUC after incorporating LA in risk models. The remaining analyses were performed with IBM ® SPSS Version 24.

Ethics statement {#s2c}
----------------

The Stony Brook University Hospital Institutional Review Board (IRB) approved this retrospective cohort study. The requirement for written informed consent from patients was waived.

Results {#s3}
=======

Population characteristics {#s3a}
--------------------------

Out of 704 patients admitted with acute GIB, 366 patients had venous LA measured within 24 h of hospital admission, of whom 30 died during their index hospitalization. The baseline demographic and clinical characteristics of these patients according to in-patient mortality status are shown in [Table 1](#T1){ref-type="table"}. Compared to survivors, patients who died in the hospital were older (mean age: 70.5 vs. 76.6 years, P = 0.021), had higher LA level (mean 2.2 vs. 5.8 mmol/L, P \< 0.0001), more likely to have albumin levels \< 3g/dL (16.4% vs. 50%, P \< 0.0001), had lower mean systolic blood pressure (127 vs. 116 mm Hg, P = 0.035), and were more likely to present with altered mental status (7.1% vs. 23.3%, P = 0.008) and syncope (5.7% vs. 16.7%, P = 0.037). The mean BUN trended higher in non-survivors (33.3 vs. 41.5 mg/dL, P = 0.058).

###### Baseline Demographic Characteristics and Test Result of Patients With Acute Gastrointestinal Bleeding According to In-Patient Mortality Status

                                                                                          Survivors (n = 336)   Non-survivors (n = 30)   All (366)      P value
  --------------------------------------------------------------------------------------- --------------------- ------------------------ -------------- -----------
  Age (years)                                                                                                                                           
    Mean (SD)                                                                             70.5 (15.9)           76.6 (16.2)              70.9 (16)      0.021
    Median (IQR)                                                                          72 (20)               80 (21)                  73 (21)        
  Gender                                                                                  148 (44%)             14 (46.7%)               162 (44.3%)    0.782
    Female, n (%)                                                                                                                                       
  Systolic blood pressure (mm Hg), mean (SD)                                              127.3 (27)            116.0 (28.6)             123.4 (27.5)   0.035
  Heart rate (beats/min), mean (SD)                                                       89.5 (21.3)           86.7 (26.7)              89.3 (21.8)    0.747
  Melena                                                                                  127 (37.8%)           12 (40%)                 139 (38%)      0.812
  Syncope in last 7 days                                                                  19 (5.7%)             5 (16.7%)                24 (6.6%)      0.037
  Altered mentation                                                                       24 (7.1%)             7 (23.3%)                31 (8.5%)      0.008
  Comorbidities                                                                                                                                         
    No major comorbidity                                                                  65 (19.3%)            2 (6.7%)                 67 (18.3%)     \< 0.0001
    Renal failure, liver failure, and/or disseminated malignancy                          120 (35.7%)           22 (73.3%)               142 (38.8%)    
    Any comorbidity except renal failure, liver failure, and/or disseminated malignancy   151 (44.9%)           6 (20.0%)                157 (42.9%)    
  Congestive heart failure                                                                74 (22%)              10 (33.3%)               84 (23%)       0.158
  Hepatic disease                                                                         43 (12.8%)            8 (26.7%)                51 (13.9%)     0.05
  Albumin \< 3g/dL                                                                        55 (16.4%)            15 (50%)                 70 (19.1%)     \< 0.0001
  INR \> 1.5                                                                              73 (21.7%)            5 (16.7%)                78 (21.3%)     0.487
  Lactic acid , peak (mmol/L), mean (SD)                                                  2.2 (1.7)             5.8 (5.5)                2.4 (2.2)      \< 0.0001
  Hemoglobin(g/dL), mean (SD)                                                             10.4 (3)              9.7 (2.7)                10.3 (3)       0.295
  BUN(mg/dL), mean (SD)                                                                   33.3 (22)             41.5 (27)                33.8 (22.8)    0.058
  Endoscopic diagnosis (n = 188)                                                                                                                        
    No lesion or stigmata of recent bleed                                                 41 (23.6%)            2 (14.3%)                43 (22.9%)     0.316
    Malignancy of upper GI tract                                                          3 (1.7%)              1 (7.1%)                 4 (2.1%)       
    All other diagnosis                                                                   130 (74.7%)           11 (78.6%)               141 (75%)      
  Hemorrhage stigmata (n = 189)                                                           67 (38.3%)            11 (78.6%)               78 (41.3%)     0.003

Furthermore, as shown in [Table 2](#T2){ref-type="table"}, non-survivors had statistically significant higher mean GBS (8 vs. 10.7, P = 0.002), RS-PE (3.6 vs. 4.6, P = 0.001), and RS-C (5.3 vs. 6.9, P = 0.004) scores while there was no difference in AIMS65 score between survivors and non-survivors (1.87 vs. 1.90, P = 0.683).

###### Clinical Risk Scores According to Inpatient Mortality Status

  Risk scores             Survivors (n = 336)   Non-survivors (n = 30)   P value
  ----------------------- --------------------- ------------------------ ---------
  Blatchford score        8 (4.6)               10.7 (4.3)               0.002
  Rockall-pre-endoscopy   3.6 (1.5)             4.6 (1.3)                0.001
  Rockall-complete\*      5.3 (2.1)             6.9 (1.3)                0.004
  AIMS65                  1.87 (0.8)            1.9 (0.8)                0.683

\*Values are mean score (SD).

In a stepwise logistic regression model that incorporated variables that were significant in the univariate analysis ([Table 3](#T3){ref-type="table"}), LA remained an independent predictor of in-hospital mortality (odds ratio (OR): 1.32 (95% CI: 1.11 - 1.57, P \< 0.0001)), as did age (OR: 1.07 (95% CI: 1.02 - 1.11, P \< 0.0001)), and albumin level (OR: 0.28 (95% CI: 0.12 - 0.64, P \< 0.0001)).

###### Binary Logistic Regression for the Prediction of In-Patient Mortality in Patients With Acute Gastrointestinal Bleeding

                            Odds ratio (OR)   95% Confidence interval for OR   P value   
  ------------------------- ----------------- -------------------------------- --------- -----------
  Age                       1.07              1.02                             1.11      \< 0.0001
  BP                        1.01              0.99                             1.03      0.37
  Hepatic disease           0.41              0.09                             1.87      0.25
  Charlson score                                                                         
    (0) Reference                                                                        0.04
    (2)                     0.55              0.09                             3.23      0.51
    (3)                     2.48              0.45                             13.54     0.3
  Syncope in last 7 days    0.9               0.19                             4.41      0.9
  Altered mentation         3.4               0.98                             11.78     0.05
  Lactic acid level, peak   1.51              1.26                             1.82      \< 0.0001
  BUN                       0.99              0.97                             1.01      0.39
  Albumin                   0.28              0.12                             0.64      \< 0.0001

The optimal LA cut-off (2.75 mmol/L) was determined by calculating the Youden's Index.

To estimate the weighted score (point) of LA in mortality prediction in the modified risk scores, we used values within the 95% CI of the beta coefficient obtained from a logistic regression model that used the same variables shown in [Table 3](#T3){ref-type="table"}, except the LA level was dichotomized at the optimal cut-off value (\< or ≥ 2.75 mmol/L) (Supplementary [Table 1](#T1){ref-type="table"}, [www.gastrores.org](http://www.gastrores.org)).

Based on the calculated beta coefficient of 2.32 ( 95% CI: 1.3 - 3.3), we added 1, 2, or 3 points to each patient's calculated risk scores if LA level is ≥ 2.75 mmol/L, thereby deriving L1-, L2-, and L3- modified risk scores. Since there was no difference in AIMS65 score between survivors and non-survivors, modified AIMS65 score was not generated.

The power of the clinical risk scores for discriminating inpatient mortality was evaluated by ROC plots and the AUC of each ROC curves ([Fig. 1](#F1){ref-type="fig"}, [Table 4](#T4){ref-type="table"}). The AUC of the original scores were: GBS AUC = 0.652 (95% CI: 0.557 - 0.747, P=0.006), RS-PE AUC = 0.675 (95% CI: 0.586 - 0.765, P = 0.001), RS-C AUC = 0.742 (95% CI: 0.633 - 0.850, P = 0.003). Venous LA was incorporated into each of these scoring modalities using the methods described above. The incorporation of LA improved the predictive value for inpatient mortality for GBS, RS-PE, and RS-C, although the increment was not statistically significant for L2-RS-C and L3-RS-C scores (where 2 and 3 points were added when LA level was \> 2.75mmol/L, respectively). The highest statistically significant improvement in AUC was seen for RS-PE, especially when 3 extra points was assigned for LA ≥ 2.75mmol/L (0.675 vs. 0.774, P = 0.012), which was comparable to or better than the RS-C (0.742, P = 0.003 (P value not show in the Table)).

![ROC curves comparing the original and modified Blatchford scores (top panel), Rockall pre-endoscope score (middle panel), and Rockall post endoscopic (complete) scores (bottom panel).](gr-12-001-g001){#F1}

###### Comparison Between Original Clinical Risk Scoring Systems and Modified Scoring System Incorporating Points (1, 2, or 3) for Lactic Acid ≥ 2.75 mmol/L

  Score                        Area    P value   95% Confidence interval   P value   
  ---------------------------- ------- --------- ------------------------- --------- ----------------------------
  Blatchford score             0.652   0.006     0.557                     0.747     Blatchford score vs.
    L1-Blatchford              0.669   0.002     0.578                     0.760     0.005
    L2-Blatchford              0.688   0.001     0.600                     0.775     0.004
    L3-Blatchford              0.706   0.000     0.621                     0.792     0.003
  Rockall Pre-Endoscopy        0.675   0.001     0.586                     0.765     Rockall pre-endoscopy vs.
    L1-Rockall pre-endoscopy   0.733   0.000     0.649                     0.818     0.003
    L2-Rockall pre-endoscopy   0.762   0.000     0.680                     0.844     0.007
    L3-Rockall pre-endoscopy   0.774   0.000     0.694                     0.854     0.012
  Rockall Score-complete       0.742   0.003     0.633                     0.850     Rockall score-complete vs.
    L1-Rockall-complete        0.780   0.000     0.677                     0.883     0.040
    L2-Rockall-complete        0.801   0.000     0.698                     0.904     0.078
    L3-Rockall-complete        0.808   0.000     0.703                     0.913     0.129

Discussion {#s4}
==========

In this retrospective study, we found that venous LA is an independent predictor of inpatient mortality in unselected patients presenting with acute gastrointestinal hemorrhage. Furthermore, the GBS, RS-PE, and RS-C scores, which were originally developed in the setting of upper GI hemorrhage are valid and applicable for the prediction of in-hospital mortality in unselected GIB patients. The AIMS65 score did not distinguish survivors from non-survivors. We also showed that incorporation of venous LA into GBS and RS showed statistically significant improvement in the power of the risk scores to discriminate inpatient mortality status. Importantly, the performance of the modified RS-PE (AUC 0.774 for L3-RS PE) was comparable to or better than that of the original RS-post endoscopic score (AUC 0.742), providing vital prognostication and risk-stratification for front-line providers before any diagnostic or therapeutic intervention has taken place.

The main strength of this study is that it aims to obviate a need to determine the site of GIB by demonstrating the validity of existing and modified clinical risk scores in mixed population of GIB patients. To our knowledge, this is the first study that has evaluated the utility of combining existing risk scores as well as the incremental value of venous LA in unselected GI bleed patients.

Our study is consistent with several other studies that evaluated the role of LA as an independent prognostic marker in patients with upper GI bleed. Stokbro et al \[[@R10]\] evaluated the incremental role of LA to clinical risk scores, specifically in upper GIB patients. They showed a statistically significant improvement in risk scores for predicting mortality by incorporating points for elevated arterial LA, at a cut-off value of 1.98 mmol/L. However, the low AUC of the modified scores in their study tempered the enthusiasm for its clinical utility. This is due to the low AUC of the risk scores prior to LA incorporation (0.54 for GBS and 0.66 for RS-PE, compared to 0.652 and 0.742, respectively, in our study). There are differences between our study and Stokbro et al that limit direct comparisons: 1) The patient population in our case is all GIB patients vs. upper GIB; 2) Our study evaluated only inpatient mortality vs. 30-day mortality; 3) We assessed venous LA vs. arterial LA, which may explain higher LA cut-off in our study since venous lactate tend to be slightly higher compared to arterial values \[[@R14]\]. Furthermore, in contrast to our finding, they found that the AIMS65 score was a superior predictor of in-hospital mortality in contrast to our findings. Multiple studies have demonstrated that the AIMS65 scoring system may be the most accurate and useful predictor for all cause in-hospital and 30-day mortality \[[@R15]-[@R18]\]. Lee et al \[[@R9]\] evaluated patients presenting with non-variceal upper GI bleeding, and found that elevated levels of venous LA were associated with increased 30-day mortality and higher rates of re-admission within 7 days. They incorporated LA into the AIMS65 score, and found that while the modified LA-AIMS65 score did have a higher AUC, the results did not reach statistical significance. It's important to highlight that the AIMS65 utilizes altered mental status as one of its criteria, a finding that is subject to inter-operator variability. In contrast, the RS-PE, RS-C, and GBS scores use objective lab and vital sign-based criteria, which can decrease error associated with inter-operator variability.

Our study has several limitations that deserve commentary. The study was conducted in a single academic tertiary care referral center, and the design was retrospective. Nearly half of the patients had serum LA levels obtained at the index of the admission; as LA may have been obtained because these patients were perceived to be more acutely ill, thus posing a possible selection bias. Only half of those with LA measured underwent endoscopic examination, likely as most of the remaining half were not suspected to have upper GI source of bleed.

In conclusion, venous LA is an important prognostic marker for inpatient mortality in unselected patients presenting with acute GI bleeding and it can improve the performance of GBS and RS-PE scores in this setting. Further investigation with larger prospective trials can explore the prognostic ability of venous LA, which may provide earlier decision making among front-line providers regarding blood and volume resuscitation, appropriate level of care, and early intervention.
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